Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRENE.L Regulatory News (RENE)

  • There is currently no data for RENE

Director/PDMR Shareholding

12 Aug 2013 07:00

RNS Number : 4202L
ReNeuron Group plc
12 August 2013
 

 

DTR3

 

NOTIFICATION OF TRANSACTIONS OF DIRECTORS/ PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND CONNECTED PERSONS

 

All relevant boxes should be completed in block capital letters.

 

1.

Name of the issuer

 

ReNeuron Group plc

2.

State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.2R; or (ii) a disclosure made in accordance with LR 9.8.6R(1); or (iii) in accordance with section 793 of the Companies Act 2006

 

(i)

 

3.

Name of person discharging managerial responsibilities/director

 

Dr. Paul Harper

4.

State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3

and identify the connected person

 

Director named in 3.

 

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest 1

 

Interest of person named in 3

 

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

 

Ordinary Shares

 

 

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

 

Person named in 3

 

8.

State the nature of the transaction

 

Placing of Ordinary Shares

9.

Number of shares, debentures or financial instruments relating to shares acquired

 

Acquisition of 200,000 Ordinary Shares

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

 

0.011%

 

11.

Number of shares, debentures or financial instruments relating to shares disposed

 

 

 

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

 

 

 

13.

Price per share or value of transaction

 

2.5 pence per Ordinary Share

 

14.

Date and place of transaction

 

9 August 2013

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

 

Dr. Paul Harper is interested in a total of 451,709 Ordinary Shares in the Company representing approximately 0.025% of issued Ordinary Shares.

 

16.

Date issuer informed of transaction

 

9 August 2013

 

If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes

 

17.

Date of grant

 

 

18.

Period during which or date on which it can be exercised

 

19.

Total amount paid (if any) for grant of the option

20.

Description of shares or debentures involved (class and number)

 

21.

Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise

 

22.

Total number of shares or debentures over which options held following notification

23.

Any additional information

 

See table of options held by Dr. Paul Harper below:

 

 

 

Number of options

Exercise Price

End of Exercise Period

98,781

12.65p

August 2015

98,688

5.07p

August 2016

258,098

12.2p

August 2017

226,682

4.85p

August 2019

277,797

4.43p

August 2020

417,274

4.31p

August 2021

500,000

3.3pp

August 2022

1,877,300

24.

Name of contact and telephone number for queries

 

Pat Huggins, Reneuron Group Plc

+44 (0)1483 302560

 

 

Name of authorised official of issuer responsible for making notification:

 

Patrick Huggins, Head of Finance and Company Secretary

 

Date of notification: 9 August 2013

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFEETIIAIIV
Date   Source Headline
6th Dec 20067:00 amRNSFiles IND Application
6th Dec 20067:00 amRNSInterim Results
30th Nov 20067:01 amRNSRe Agreement
20th Nov 20067:00 amRNSMarket Launch of ReNcell
15th Nov 20067:02 amRNSExercise of Warrants
9th Oct 20069:50 amRNSTo Present Data in October
21st Sep 200611:49 amRNSRe: Warrant Holder Meeting
21st Sep 200611:45 amRNSAGM Statement
19th Sep 20063:39 pmRNSIssue of Equity
4th Sep 20065:31 pmRNSDirector/PDMR Shareholding
4th Sep 20065:31 pmRNSDirector/PDMR Shareholding
4th Sep 20065:23 pmRNSDirector/PDMR Shareholding
4th Sep 20065:18 pmRNSDirector/PDMR Shareholding
30th Aug 200612:03 pmRNSHolding(s) in Company
30th Aug 200611:57 amRNSHolding(s) in Company
23rd Aug 20063:19 pmRNSAGM
23rd Aug 20067:01 amRNSRe: Clinical Investigator
29th Jun 20062:21 pmRNSHolding(s) in Company
29th Jun 20067:02 amRNSResearch Update
28th Jun 20067:01 amRNSRe Placing
28th Jun 20067:01 amRNSFinal Results
26th Jun 20063:27 pmRNSNotice of Results
5th Jun 20067:02 amRNSConference
11th May 20062:35 pmRNSHolding(s) in Company
26th Apr 20065:17 pmRNSDirector/PDMR Shareholding
26th Apr 20065:13 pmRNSDirector/PDMR Shareholding
26th Apr 20065:09 pmRNSDirector/PDMR Shareholding
26th Apr 20065:03 pmRNSDirector/PDMR Shareholding
26th Apr 20064:59 pmRNSDirector/PDMR Shareholding
18th Apr 20067:02 amRNSRe Agreement
18th Apr 20067:02 amRNSRe Agreement
10th Apr 20061:52 pmRNSHolding(s) in Company
5th Apr 20069:08 amRNSIntention to raise funds
4th Apr 20069:52 amRNSResearch Update
8th Mar 20067:32 amRNSResearch Update
7th Mar 20067:00 amRNSRe: BioSquare Conference
16th Feb 20067:01 amRNSResearch Update
7th Feb 20067:01 amRNSRe: Manufacturing Contract
6th Feb 20067:01 amRNSResearch Update
24th Jan 20067:00 amRNSRe US Patent Office
6th Dec 200510:03 amRNSRe Conference
2nd Dec 200511:19 amRNSRe: Government Support
30th Nov 20057:00 amRNSInterim Results
23rd Nov 20054:57 pmRNSNotice of Results
18th Nov 20057:00 amRNSResearch Update
25th Oct 20057:00 amRNSResearch Update
5th Oct 20059:59 amRNSHolding(s) in Company
22nd Sep 200510:31 amRNSResearch Update
20th Sep 20059:13 amRNSDirector/PDMR Shareholding
16th Sep 20051:08 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.